Nuclidium

Basel, Switzerland · Founded 2017 · Privately Held (backing)

Developer of novel radiopharmaceutical tracers designed to target cancer diagnostics. Nuclidium is based in Basel, Switzerland and was founded in 2017. Its last reported valuation was $163 million in Jul 2025. It has raised $101 million.

Last reported valuation
$163.2M
Oct 2026
Priced at
—
Total raised
$100.6M
Last round
—

Who backs Nuclidium?

13 investors
InvestorType
InnosuisseOther
Bayern KapitalVenture capital
Highlight CapitalOther
NRW.BankOther
Kurma PartnersVenture capital
NEVA SGRVenture capital
Wellington PartnersVenture capital
Angelini VenturesVenture capital
Anthony Wild—
DeepTech & Climate Fonds—
+ 3 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Nuclidium investors

13 investors are on record for Nuclidium, including Innosuisse, Bayern Kapital, Highlight Capital and NRW.Bank. By type, the record holds 5 venture capital firms.

Free account
More of Nuclidium with a free account
  • ·The complete investor list: 13 names
  • ·Watch Nuclidium: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 13 firms already write checks for companies like Nuclidium. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View